Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Athol U. Wells Clear advanced filters

  • Pulmonary complications are an important extra-articular manifestation of connective tissue disease (CTD) and a major cause of mortality. Here, the authors provide a broad overview of interstitial lung disease in the context of CTD, providing insights into pathogenesis, classification and management of the disease.

    • Athol U. Wells
    • Christopher P. Denton
    Reviews
    Nature Reviews Rheumatology
    Volume: 10, P: 728-739

  • Tasha Fingerlin, David Schwartz and colleagues report a genome-wide association study of fibrotic idiopathic interstitial pneumonia. Their results confirm known risk variants at MUC5B and TERT and identify several new regions associated with disease susceptibility.

    • Tasha E Fingerlin
    • Elissa Murphy
    • David A Schwartz
    Research
    Nature Genetics
    Volume: 45, P: 613-620

  • Interstitial lung disease (ILD) can arise in a variety of connective tissue diseases (CTDs) and various treatment interventions are being explored. In 2020, advances in the treatment of CTD-associated ILD have included the re-evaluation of methotrexate-induced lung injury and emerging insights on anti-IL-6 therapy and anti-fibrotic therapy in this condition.

    • Athol U. Wells
    News & Views
    Nature Reviews Rheumatology
    Volume: 17, P: 79-80

  • Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive lung scarring that is thought to occur in a genetically susceptible, ageing individual through aberrant reparative responses to repeated injury to the alveolar epithelium. This Primer summarizes the processes thought to underlie the development of IPF and clinical challenges faced in treating patients with this irreversible condition.

    • Fernando J. Martinez
    • Harold R. Collard
    • Athol U. Wells
    Reviews
    Nature Reviews Disease Primers
    Volume: 3, P: 1-19

  • The two major lung complications in systemic sclerosis, lung fibrosis and pulmonary arterial hypertension, share some pathogenic mechanisms. Strategies for managing patients with these complications have greatly advanced in the past decade, and many tools and treatments are now available.

    • Christopher P. Denton
    • Athol U. Wells
    • John G. Coghlan
    Reviews
    Nature Reviews Rheumatology
    Volume: 14, P: 511-527